The Cipla share price saw a massive 3.7% cut in trade today (October 24).The stock has been in focus after the pharma major signed a distribution and promotion agreement with Eli Lilly for tirzepatide (under a second brand named ‘Yurpeak’) in India. The pact is expected to lift Eli Lilly’s secondary sales but what’s in it for Cipla? Key brokerage house Nuvama raised the target price for Cipla to Rs 1,725 as they believe it will get a head start as a result of this deal. They have, however, retained the ‘Hold’ recommendation.

Nuvama on Cipla: FY26 revenue boost expected

Eli Lilly would supply the drug to Cipla , which would then be sold by Cipla at a price equivalent to Mounjaro. Outlining what the deal entails for Cipla, Nuvama pointed out that “Mounjaro’s secondary sales stood a

See Full Page